Daniel Kavanagh, PhD, RAC
Senior Scientific Advisor, Gene Therapy, Vaccines & Biologics, WCG
Biography
Daniel Kavanagh, PhD, RAC, is the senior scientific advisor of gene therapy, vaccines, and biologics at WCG. Prior to joining WCG, he was assistant professor of medicine and Institutional Biosafety Committee vice chair at Harvard Medical School, and assistant immunologist at the Massachusetts General Hospital. He was also co-chair of a Phase 1 clinical trial of a therapeutic mRNA vaccine. He is certified in US Regulatory Affairs (RAC) by the Regulatory Affairs Professional Society.
Latest insights by Daniel
WCG Clinical | Insights
Key Takeaways From FDA’s New Draft Guidance, “Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial”
Blog Posts
WCG Clinical | Insights
[Video] Institutional Biosafety Committee Review: Strategies to Secure Rapid IBC Approval for Human Gene Transfer Trials
Videos
WCG Clinical | Insights
Four Key Elements You Need to Know About the Role of IBCs in Gene Therapy Trials
Articles
WCG Clinical | Insights
As a sponsor, does my HGT clinical trial require IBC approval at all sites?
Blog Posts
WCG Clinical | Insights
Does Human Gene Transfer research at my site require IBC approval?
Blog Posts
WCG Clinical | Insights
Institutional Biosafety Committee Review for Genetically Modified Vaccines and Gene Transfer Products
Videos
WCG Clinical | Insights
NIH Launches NExTRAC to Advise on Emerging Biotechnologies
Blog Posts
WCG Clinical | Insights
Amendments to the NIH Guidelines: Effects on Human Gene Transfer Research
Blog Posts
WCG Clinical | Insights
Germline Modification for HIV Prevention is Unjustified
Blog Posts
WCG Clinical | Insights